EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Preliminary clinical experience with Infliximab in the treatment of refractory and fistulizing Crohns disease



Preliminary clinical experience with Infliximab in the treatment of refractory and fistulizing Crohns disease



Gastroenterology 118(4 Suppl 2 Part 1): AGA A565, April




(PDF emailed within 1 workday: $29.90)

Accession: 035539954

Download citation: RISBibTeXText



Related references

Efficacy and safety of infliximab treatment for refractory and fistulizing Crohns disease in a Dutch expanded access program. Gastroenterology 118(4 Suppl 2 Part 1): AGA A588, April, 2000

Effect of antibodies to infliximab on infusion reaction and clinical response in patients with fistulizing crohns disease receiving maintenance treatment with infliximab. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No M1598, 2003

Treatment of fistulizing Crohns disease with infliximab One year follow by MR-scan, ultrasound and clinical examination. Gastroenterology 122(4 Suppl 1): A 613, April, 2002

Consistent treatment benefit with infliximab in patients with fistulizing Crohns disease. Gastroenterology 116(4 PART 2): A788, April, 1999

Treatment of perianal fistulizing Crohns disease with infliximab alone or as an adjunct to exam under anesthesia. Gastroenterology 122(4 Suppl 1): A 614, April, 2002

Treatment with infliximab in patients with fistulizing crohns disease efficacy and predictors of response. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No T1369, 2003

Pretreatment with 6-mercaptopurine/azathioprine prolongs clinical response time in Crohns disease patients with fistulizing disease treated with infliximab. Gastroenterology 118(4 Suppl 2 Part 1): AGA A788, April, 2000

Long-term treatment of fistulizing Crohns disease Response to infliximab in the ACCENT II trial through 54 weeks. Gastroenterology 122(4 Suppl 1): A 81-A 82, April, 2002

Long-term oral tacrolimus in refractory to infliximab fistulizing Crohn's disease: comments from Spanish experience. Gastroenterology 126(3): 942-3; Author Reply 943, 2004

Infliximab therapy for fistulizing Crohns disease. American Journal of Gastroenterology 95(9): 2635, September, 2000

Clinical efficacy of treatment with infliximab in a German multicenter, prospective, open-label trial in refractory Crohns disease. Gastroenterology 118(4 Suppl 2 Part 1): AGA A568, April, 2000

Infliximab pharmacokinetics and improvement in fistulizing crohns disease. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No 470, 2003

MRI imaging of the effects of infliximab in perianal fistulizing Crohns disease. Gastroenterology 120(5 Supplement 1): A 68, April, 2001

Collaborative experience of open-label infliximab in refractory pediatric Crohns disease. JPGN 31(Supplement 2): S227, 2000